Stock 1099 SINOPHARM GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Sinopharm Group Co., Ltd. Share Price Shanghai - Hong Kong Stock Connect

Equities

1099

CNE100000FN7

Pharmaceuticals

Financials

Sales 2024 * 649B 89.62B 701B 7,477B Sales 2025 * 707B 97.61B 763B 8,144B Capitalization 57.3B 7.91B 61.86B 660B
Net income 2024 * 9.61B 1.33B 10.38B 111B Net income 2025 * 10.58B 1.46B 11.43B 122B EV / Sales 2024 * 0.11 x
Net Debt 2024 * 11.49B 1.59B 12.41B 132B Net Debt 2025 * 9.36B 1.29B 10.1B 108B EV / Sales 2025 * 0.09 x
P/E ratio 2024 *
5.95 x
P/E ratio 2025 *
5.41 x
Employees -
Yield 2024 *
5.09%
Yield 2025 *
5.59%
Free-Float 42.99%
More Fundamentals * Assessed data

Chart Sinopharm Group Co., Ltd.

Dynamic Chart

Latest news about Sinopharm Group Co., Ltd.

Wall Street Cues, Property Outlooks Lift Asian Stock Markets MT
China, Hong Kong stocks rise, led by property shares RE
Sinopharm Group Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit DJ
Sinopharm Group's Q1 Profit Falls as Operating Costs Rise MT
Central Bank, Tech Outlooks Lift Major Asian Stock Markets MT
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue MT
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024 CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6% MT
US Inflation, Light News Flow Churns Asian Stock Markets MT
More news

Analyst Recommendations on Sinopharm Group Co., Ltd.

Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy MT
Interest Rates, Earnings, FX Roil Asian Stock Markets MT
Nomura Adjusts Sinopharm Group's Price Target to HK$33.31 From HK$36.28, Keeps at Buy MT
Nomura Adjusts Sinopharm's Price Target to HK$36.28 From HK$36.88, Keeps at Buy MT
UBS Adjusts Sinopharm Group's Price Target to HK$26 From HK$28, Keeps at Buy MT
More recommendations

Press releases Sinopharm Group Co., Ltd.

Sinopharm : 2023 Interim Results Presentation PU
Sinopharm : 2022 Annual Results Presentation PU
Sinopharm : 2022 Interim Report PU
Sinopharm : 2021 Interim Report PU
Sinopharm : FORM OF PROXY FOR DOMESTIC SHAREHOLDERS' CLASS MEETING PU
More press releases

News in other languages on Sinopharm Group Co., Ltd.

Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi
MÄRKTE ASIEN/Trotz Zinssenkung erneute Verluste in Hongkong und Schanghai
MORNING BRIEFING - USA/Asien
Borsa: Country Garden in uscita dall'Hang Seng di Hong Kong
MÄRKTE ASIEN/Erneute Abgaben in Hongkong und Schanghai
More news

Managers and Directors - Sinopharm Group Co., Ltd.

Managers TitleAgeSince
Yong Liu PSD
 President 55 09/09/09
Shuang Jun Xu PRN
 Corporate Officer/Principal 55 01/11/01
Zhong Xi Cai PRN
 Corporate Officer/Principal 59 01/10/01
Members of the board TitleAgeSince
Qi Yu Chen BRD
 Director/Board Member 52 01/10/01
Xiao Hui Guan BRD
 Director/Board Member 53 11/19/11
Yi Jian Wu SEC
 Corporate Secretary 54 -
More insiders

Company Profile

Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
Sector
Pharmaceuticals
Calendar
13/06/2024 - Annual General Meeting
Related indices
HONG KONG HANG SENG
More about the company

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+14.71% 69.79B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+1.36% 24.85B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+7.11% 8.2B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.55% 7.96B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+3.48% 4.69B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.32B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.24% 3.99B
GALENICA AG Stock Galenica AG
-2.96% 3.81B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+21.42% 3.62B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 1099 Stock
  4. 1099 Stock